Kymera IPO Presentation Deck slide image

Kymera IPO Presentation Deck

CANCER FIBROSIS Liquid Tumors KYMERA Autoimmune Fibrosis STAT3 Protein (% Control) STAT3 Degradation 150 125- 100 50 STAT3 Degradation and Downstream Effects Across Tumor Cells 25 -SU-DHL-1 SUP-MZ 0 1 2 3 Log [STAT3 Degrader] (nM) • STAT3 protein levels measured in two STAT3-dependent cell lines • STAT3 degrader decreased levels of STAT3 by greater than 95% with DC so of 15nM and 86 nM, respectively Gene Transcription Effects mRNA Levels (% Control) 125 100 75 50- 25 Socs3 +Myc 0 1 2 3 Log (STAT3 Degrader] (n) Expression of STAT3 downstream target genes in SU-DHL-1 cells measured Treatment with STAT3 degrader for 24 hours led to significant downregulation of STAT3 target genes, including SOCS3 (ICS = 36 nM) and MYC (IC=37 nM) Growth Inhibition (% Control) Cell Viability Effects 125 100- 75- 50 25- -SU-DHL-1 SUP-M2 -1 0 1 2 3 4 Log [STAT3 Degrader] (nM) 5 Impact of STAT3 degradation on viability of lymphoma cells measured . Inhibited growth of SU-DHL-1 and SUP- M2 cells with IC50 values of 64 and 105 nM, respectively
View entire presentation